Cellular chromium enhances activation of insulin receptor kinase

Biochemistry

Volumn 44, Issue 22, 2005, Pages 8167-8175

  Wang, Hong ^a   Kruszewski, Allison ^a   Brautigan, David L ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOASSAY; BIOLOGICAL MEMBRANES; CELLS; CHROMIUM; ENZYME INHIBITION; GLUCOSE; INSULIN; MOLECULAR DYNAMICS; NUTRITION; REDOX REACTIONS;

CELLULAR CHROMIUM; INSULIN RECEPTOR KINASE; PLASMA MEMBRANES; TYROSINE PHOSPHORYLATION;

ENZYMES;

4 NITROPHENYL PHOSPHATE; CHROMIUM; CHROMIUM CHLORIDE; CHROMIUM PICOLINATE; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR KINASE; INSULIN RECEPTOR SUBSTRATE 1; PROTEIN TYROSINE PHOSPHATASE; RECOMBINANT ENZYME;

ANIMAL CELL; ARTICLE; CELL LINE; CELL MEMBRANE; CHO IR CELL; CONTROLLED STUDY; DRUG DESIGN; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; GLUCOSE TOLERANCE; HORMONE ACTION; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRITION; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; ANIMALS; CELL MEMBRANE; CHO CELLS; CHROMIUM; CRICETINAE; ENZYME ACTIVATION; ENZYME INHIBITORS; GLUTATHIONE TRANSFERASE; HUMANS; INSULIN; MOLECULAR SEQUENCE DATA; OXIDATION-REDUCTION; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY; PROTEIN-TYROSINE-PHOSPHATASE; RECEPTOR, INSULIN; RECOMBINANT FUSION PROTEINS; TYROSINE;

EID: 20144370807     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi0473152     Document Type: Article

References (65)

1. Committee on Animal Nutrition Board on Agriculture National Research Council (1997) The Role of Chromium in Animal Nutrition, National Academy Press, Washington, DC.
2. Jeejeebhoy, K. N., Chu, R. C., Marliss, E. B., Greenberg, G. R., and Bruce-Robertson. A. (1977) Chromium deficiency, glucose intolerance, and neuropathy reversed by chromium supplementation, in a patient receiving long-term total parenteral nutrition, Am. J. Clin. Nutr. 30, 531-538.
3. Freund, H., Atamian, S., and Fischer, J. E. (1979) Chromium deficiency during total parenteral nutrition, JAMA, J. Am. Med. Assoc. 241, 496-498.
4. Kien, C. L., Veillon, C., Patterson, K. Y., and Farrell, P. M. (1986) Mild peripheral neuropathy but biochemical chromium sufficiency during 16 months of "chromium-free" total parenteral nutrition, JPEN, J. Parenter. Enteral Nutr. 10, 662-664.
5. Brown, R. O., Forloines-Lynn, S., Cross, R. E., and Heizer, W. D. (1986) Chromium deficiency after long-term total parenteral nutrition, Dig. Dis. Sci. 31, 661-664.
6. Anderson, R. A. (1995) Chromium and parenteral nutrition, Nutrition 11, 83-86.
7. Anderson, R. A. (1998) Chromium, glucose intolerance and diabetes, J. Am. Coll. Nutr. 17, 548-555.
8. Ryan, G. J., Wanko, N. S., Redman, A. R., and Cook, C. B. (2003) Chromium as adjunctive treatment for type 2 diabetes, Ann. Pharmacother. 37, 876-885.
9. Anderson, R. A., Cheng, N., Bryden, N. A., Polansky, M. M., Chi, J., and Feng, J. (1997) Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes, Diabetes 46, 1786-1791.
10. Cheng, N., Zhu, X., Shi, H., Wu, W., Chi, J., Cheng, J., and Anderson, R. A. (1999) Follow-up survey of people in China with type 2 diabetes mellitus consuming supplemental chromium, J. Trace Elem. Exp. Med. 12, 55-60.
11. Jovanovic, L., Gutierrez, M., and Peterson, C. M. (1999) Chromium supplementation for women with gestational diabetes mellitus, J. Trace Elem. Exp. Med. 12, 91-97.
12. Ravina, A., Slezak, L., Mirsky, N., Bryden, N. A., and Anderson, R. A. (1999) Reversal of corticosteroid-induced diabetes mellitus with supplemental chromium. Diabetes Med. 16, 164-167.
13. Cefalu, W. T., Bell-Farrow, A. D., Stegner, J., Wang, Z. Q., King, T., Morgan, T., and Terry, J. G. (1999) Effect of chromium picolinate on insulin sensitivity in vivo, J. Trace Elem. Exp. Med. 12, 71-83.
14. Abraham, A. S., Brooks, B. A., and Eylath, U. (1992) The effects of chromium supplementation on serum glucose and lipids in patients with and without non-insulin-dependent diabetes, Metabolism 41, 768-771.
15. Thomas, V. L., and Cropper, S. S. (1996) Effect of chromium nicotinic acid supplementation on selected cardiovascular disease risk factors, Biol. Trace Elem. Res. 55, 297-305.
16. Morris, B. W., Kouta, S., Robinson, R., MacNeil, S., and Heller, S. (2000) Chromium supplementation improves insulin resistance in patients with type 2 diabetes mellitus, Diabetes Med. 17, 684-685.
17. Sherman, L., Glennon, J. A., Brech, W. J., Klomberg, G. H., and Gordon, E. S. (1968) Failure of trivalent chromium to improve hyperglycemia in diabetes mellitus, Metabolism 17, 439-442.
18. Trow, L. G., Lewis, J., Greenwood, R. H., Sampson, M. J., Self, K. A., Crews, H. M., and Fairweather-Tait, S. J. (2000) Lack of effect of dietary chromium supplementation on glucose tolerance, plasma insulin and lipoprotein levels in patients with type 2 diabetes, Int. J. Vitam. Nutr. Res. 70, 14-18.
19. Amato, P., Morales, A. J., and Yen, S. S. (2000) Effects of chromium picolinate supplementation on insulin sensitivity, serum lipids, and body composition in healthy, nonobese, older men and women, J. Gerontol., Ser. A 55, M260-M263.
20. Wilson, B. E., and Gondy, A. (1995) Effects of chromium supplementation on fasting insulin levels and lipid parameters in healthy, non-obese young subjects, Diabetes Res. Clin. Pract. 28. 179-184.
21. Anderson, R. A., Polansky, M. M., Bryden, N. A., Roginski, E. E., Mertz, W., and Glinsmann, W. (1983) Chromium supplementation of human subjects: Effects on glucose, insulin, and lipid variables, Metabolism 32, 894-899.
22. Offenbacher, E. G., Rinko, C. J., and Pi-Sunyer, F. X. (1985) The effects of inorganic chromium and brewer's yeast on glucose tolerance, plasma lipids, and plasma chromium in elderly subjects, Am. J. Clin. Nutr. 42, 454-461.
23. Mertz, W., and Schwarz, K. (1959) Relation of glucose tolerance factor to impaired intravenous glucose tolerance of rats on stock diets, Am. J. Physiol. 196, 614-618.
24. Schwarz, K., and Mertz, W. (1959) Chromium(III) and the glucose tolerance factor, Arch. Biochem. Biophys. 85, 292-295.
25. Toepfer, E. W., Mertz, W., Polansky, M. M., Roginski, E. E., and Wolf, W. R. (1977) Preparation of chromium-containing material of glucose tolerance factoi activity from brewer's yeast extracts and by synthesis, J. Agric. Food Chem. 25, 162-166.
26. Mertz, W. (1975) Effects and metabolism of glucose tolerance factor, Nutr. Rev. 33, 129-135.
27. Yamamoto, A., Wada, O., and Ono, T. (1987) Isolation of a biologically active low-molecular-mass chromium compound from rabbit liver, Eur. J. Biochem. 165, 627-631.
28. Davis, C. M., and Vincent, J. B. (1997) Isolation and characterization of a biologically active chromium oligopeptide from bovine liver, Arch. Biochem. Biophys. 339, 335-343.
29. Sun, Y., Ramirez, J., Woski, S. A., and Vincent, J. B. (2000) The binding of trivalent chromium to low-molecular-weight chromium-binding substance (LMWCr) and the transfer of chromium from transferrin and chromium picolinate to LMWCr, J. Biol. Inorg. Chem. 5, 129-136.
30. Vincent, J. B. (1999) Mechanisms of chromium action: Low-molecular-weight chromium-binding substance, J. Am. Coll. Nutr. 18, 6-12.
31. + decreases plasma cholesterol and triglycerides in rats: Towards chromium-containing therapeutics, J. Biol. Inorg. Chem. 4, 838-845.
32. + decreases plasma insulin, cholesterol, and triglycerides in healthy and type II diabetic rats but not type I diabetic rats, J. Biol. Inorg. Chem. 7, 852-862.
33. Bandyopadhyay, D., Kusari, A., Kenner, K. A., Liu, F., Chernoff, J., Gustafson, T. A., and Kusari, J. (1997) Protein-tyrosine phosphatase 1B complexes with the insulin receptor in vivo and is tyrosine-phosphorylated in the presence of insulin. J. Biol. Chem. 272, 1639-1645.
34. Kenner, K. A., Anyanwu, E., Olefsky, J. M., and Kusari, J. (1996) Protein-tyrosine phosphatase 1B is a negative regulator of insulin- and insulin-like growth factor-I-stimulated signaling. J. Biol. Chem. 271, 19810-19816.
35. Walchli, S., Curchod, M. L., Gobert, R. P., Arkinstall, S., and Hooft van Huijsduijnen, R. (2000) Identification of tyrosine phosphatases that dephosphorylats the insulin receptor. A brute force approach based on "substrate-trapping" mutants. J. Biol. Chem. 275, 9792-9796.
36. Elchebly, M., Payette, P., Michaliszyn, E., Cromlish, W., Collins, S., Loy, A. L., Normandin, D., Cheng, A., Himms-Hagen, J., Chan, C. C., Ramachandran, C., Gresser, M. J., Tremblay, M. L., and Kennedy, B. P. (1999) Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene, Science 283, 1544-1548.
37. Klaman, L. D., Boss, O., Peroni, O. D., Kim, J. K., Martino, J. L., Zabolotny, J. M., Moghal, N., Lubkin, M., Kim, Y. B., Sharpe, A. H., Stricker-Krongrad, A., Shulman, G. I., Neel, B. G., and Kahn, B. B. (2000) Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice, Mol. Cell. Biol. 20, 5479-5489.
38. Zinker, B. A., Rondinone, C. M., Trevillyan, J. M., Gum, R. I., Clampit, J. E., Waring, J. F., Xie, N., Wilcox, D., Jacobson, P., Frost, L., Kroeger, P. E., Reilly, R. M., Koterski, S., Opgenorth, T. J., Ulrich, R. G., Crosby, S., Butler, M., Murray, S. F., McKay, R. A., Bhanot, S., Monia, B. P., and Jirousek, M. R. (2002) PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice, Proc. Natl. Acad. Sci. U.S.A. 99, 11357-11362.
39. Xin, Z., Oost, T. K., Abad-Zapatero, C., Hajduk, P. J., Pei, Z., Szczepankiewicz, B. G., Hutchins, C. W., Ballaron, S. J., Stashko, M. A., Lubben, T., Trevillyan, J. M., Jirousek, M. R., and Liu, G. (2003) Potent, selective inhibitors of protein tyrosine phosphatase 1B, Bioorg. Med. Chem. Lett. 13, 1887-1890.
40. Johnson, T. O., Ermolieff, J., and Jirousek, M. R. (2002) Protein tyrosine phosphatase 1B inhibitors for diabetes, Nat. Rev. Drug Discovery 1, 696-709.
41. Szczepankiewicz, B. G., Liu, G., Hajduk, P. J., Abad-Zapatero, C., Pei, Z., Xin, Z., Lubben, T. H., Trevillyan, J. M., Stashko, M. A., Ballaron, S. J., Liang, H., Huang, F., Hutchins, C. W., Fesik, S. W., and Jirousek, M. R. (2003) Discovery of a potent, selective protein tyrosine phosphatase 1B inhibitor using a linked-fragment strategy, J. Am. Chem. Soc. 125, 4087-4096.
42. Shim, Y. S., Kim, K. C., Chi, D. Y., Lee, K. H., and Cho, H. (2003) Formylchromone derivatives as a novel class of protein tyrosine phosphatase 1B inhibitors, Bioorg. Med. Chem. Lett. 13, 2561-2563.
43. Davis, C. M., Sumrall, K. H., and Vincent, J. B. (1996) A biologically active form of chromium may activate a membrane phosphotyrosine phosphatase (PTP), Biochemistry 35, 12963-12969.
44. Davis, C. M., and Vincent, J. B. (1997) Chromium oligopeptide activates insulin receptor tyrosine kinase activity, Biochemistry 36, 4382-4385.
45. Anderson, R. A., Polansky, M. M., Bryden, N. A., Patterson, K. Y., Veillon, C., and Glinsmann, W. H. (1983) Effects of chromium supplementation on urinary Cr excretion of human subjects and correlation of Cr excretion with selected clinical parameters, J. Nutr. 113, 276-281.
46. Thom, D., Powell, A. J., Lloyd, C. W., and Rees, D. A. (1977) Rapid isolation of plasma membranes in high yield from cultured fibroblasts, Biochem. J. 168, 187-194.
47. Brautigan, D. L., Bornstein, P., and Gallis, B. (1981) Phosphotyrosyl-protein phosphatase. Specific inhibition by Zn, J. Biol. Chem. 256, 6519-6522.
48. Mahadev, K., Zilbering, A., Zhu, L., and Goldstein, B. J. (2001) Insulin-stimulated hydrogen peroxide reversibly inhibits protein-tyrosine phosphatase 1b in vivo and enhances the early insulin action cascade, J. Biol. Chem. 276, 21938-21942.
49. Mahadev, K., Wu, X., Zilbering, A., Zhu, L., Lawrence, J. T., and Goldstein, B. J. (2001) Hydrogen peroxide generated during cellular insulin stimulation is integral to activation of the distal insulin signaling cascade in 3T3-L1 adipocytes, J. Biol. Chem. 276, 48662-48669.
50. Shoelson, S. E., Chatterjee, S., Chaudhuri, M., and White, M. F. (1992) YMXM motifs of IRS-1 define substrate specificity of the insulin receptor kinase, Proc. Natl. Acad. Sci. U.S.A. 89, 2027-2031.
51. Cefalu, W. T., Wang, Z. Q., Zhang, X. H., Baldor, L. C., and Russell, J. C. (2002) Oral chromium picolinate improves carbohydrate and lipid metabolism and enhances skeletal muscle Glut-4 translocation in obese, hyperinsulinemic (JCR-LA corpulent) rats, J. Nutr. 132, 1107-1114.
52. Cefalu, W. T. (2003) in Chromium in Health and Disease, A Cadre Research Summit, pp 29, Boston.
53. Cefalu, W. T. (2003) 18th International Diabetes Federation Congress, Paris, France.
54. Fukuhara, A., Matsuda, M., Nishizawa, M., Segawa, K., Tanaka, M., Kishimoto, K., Matsuki, Y., Murakami, M., Ichisaka, T., Murakami, H., Watanabe, E., Takagi, T., Akiyoshi, M., Ohtsubo, T., Kihara, S., Yamashita, S., Makishima, M., Funahashi, T., Yamanaka, S., Hiramatsu, R., Matsuzawa, Y., and Shimomura, I. (2005) Visfatin: A protein secreted by visceral fat that mimics the effects of insulin, Science 307, 426-430.
55. Yamamoto, A., Wada, O., and Suzuki, H. (1988) Purification and properties of biologically active chromium complex from bovine colostrum, J. Nutr. 118, 39-45.
56. Salmeen, A., Andersen, J. N., Myers, M. P., Meng, T. C., Hinks, J. A., Tonks, N. K., and Barford, D. (2003) Redox regulation of protein tyrosine phosphatase 1B involves a sulphenyl-amide intermediate, Nature 423, 769-773.
57. van Montfort, R. L., Congreve, M., Tisi, D., Carr, R., and Jhoti, H. (2003) Oxidation state of the active-site cysteine in protein tyrosine phosphatase 1B, Nature 423, 773-777.
58. Takayama, S., White, M. F., and Kahn, C. R. (1988) Phorbol ester-induced serine phosphorylation of the insulin receptor decreases its tyrosine kinase activity, J. Biol. Chem. 263, 3440-3447.
59. Strack, V., Hennige, A. M., Krutzfeldt, J., Bossenmaier, B., Klein, H. H., Kellerer, M., Lammers, R., and Haring, H. U. (2000) Serine residues 994 and 1023/25 are important for insulin receptor kinase inhibition by protein kinase C isoforms β2 and θ, Diabetologia 43, 443-449.
60. Hirosumi, J., Tuncman, G., Chang, L., Gorgun, C. Z., Uysal, K. T., Maeda, K., Karin, M., and Hotamisligil, G. S. (2002) A central role for JNK in obesity and insulin resistance, Nature 420, 333-336.
61. Nakatani, Y., Kaneto, H., Kawamori, D., Hatazaki, M., Miyatsuka, T., Matsuoka, T. A., Kajimoto, Y., Matsuhisa, M., Yamasaki, Y., and Hori, M. (2004) Modulation of the JNK pathway in liver affects insulin resistance status, J. Biol. Chem. 279, 45803-45809.
62. de Alvaro, C., Teruel, T., Hernandez, R., and Lorenzo, M. (2004) Tumor necrosis factor α produces insulin resistance in skeletal muscle by activation of inhibitor κB kinase in a p38 MAPK-dependent manner, J. Biol. Chem. 279, 17070-17078.
63. Ozcan, U., Cao, Q., Yilmaz, E., Lee, A. H., Iwakoshi, N. N., Ozdelen, E., Tuncman, G., Gorgun, C., Glimcher, L. H., and Hotamisligil, G. S. (2004) Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes, Science 306, 457-461.
64. Sugita, M., Sugita, H., and Kaneki, M. (2004) Increased insulin receptor substrate 1 serine phosphorylation and stress-activated protein kinase/c-Jun N-terminal kinase activation associated with vascular insulin resistance in spontaneously hypertensive rats, Hypertension 44, 484-489.
65. Kreuzer, J., Nurnberg, B., and Krieger-Brauer, H. I. (2004) Ligand-dependent autophosphorylation of the insulin receptor is positively regulated by Gi-proteins, Biochem. J. 380, 831-836.